La lecture à portée de main
Editeur
Suivre pivotal-therapeutics-inc
Documents
Pivotal Therapeutics cierra financiación
Documents
Pivotal Therapeutics Closes Financing; Receives Over CDN $7.7 Million to Further VASCAZEN® Commercialization
Documents
Médias
Pivotal Therapeutics Closes Financing; Receives Over CDN $7.7 Million to Further VASCAZEN® Commercialization
6 pages
English
Documents
Pivotal Therapeutics anuncia una Notificación de Aprobación para su formulación 6:1 EPA:DHA
Documents
Médias
Pivotal Therapeutics anuncia una Notificación de Aprobación para su formulación 6:1 EPA:DHA
6 pages
Español
Documents
Pivotal Therapeutics Announces Notice of Allowance for U.S. Patent on its Unique 6:1 EPA:DHA Formulation
Documents
Médias
Pivotal Therapeutics Announces Notice of Allowance for U.S. Patent on its Unique 6:1 EPA:DHA Formulation
5 pages
English
Documents
Respaldo positivo de Pivotal Therapeutics Inc. en el European Society of Cardiology Congress 2012
Documents
Médias
Respaldo positivo de Pivotal Therapeutics Inc. en el European Society of Cardiology Congress 2012
3 pages
Español
Documents
Pivotal Therapeutics Inc. Generates Positive Feedback at European Society of Cardiology Congress 2012
Documents
Médias
Pivotal Therapeutics Inc. Generates Positive Feedback at European Society of Cardiology Congress 2012
2 pages
English
Documents
Muestra de Pivotal Therapeutics en el European Society of Cardiology Congress 2012
Documents
Médias
Muestra de Pivotal Therapeutics en el European Society of Cardiology Congress 2012
2 pages
Español
Documents
Pivotal Therapeutics Exhibiting at European Society of Cardiology Congress 2012
Documents
Médias
Pivotal Therapeutics Exhibiting at European Society of Cardiology Congress 2012
2 pages
English
Documents
Pivotal anuncia una presentación científica en el 17th World Congress on Heart Disease
Documents
Médias
Pivotal anuncia una presentación científica en el 17th World Congress on Heart Disease
3 pages
Español
Documents
Pivotal Announces Scientific Presentation at the 17th World Congress on Heart Disease Demonstrating Superiority of VASCAZEN™ Unique Formulation
Documents
Médias
Pivotal Announces Scientific Presentation at the 17th World Congress on Heart Disease Demonstrating Superiority of VASCAZEN™ Unique Formulation
2 pages
English